Strategies for enhancing GLP-1  signaling in diabetic subjects represent appropriate pharmacological targets and include:

1) Delivery of potent GLP-1  analogues via s.c., enteral, pulmonary, or sublingual delivery systems

2) Cell-based GLP-1  delivery

3) Gene therapy for long acting GLP-1  delivery

The latter 2 strategies would ideally employ endogenous and/or heterologous nutrient sensitive promoters for control of GLP-1  secretion

4) Molecules that would activate GLP-1 receptor signaling in target tissues

5) Molecules that would stimulate GLP-1  release from the endogenous enteroendocrine L cell

A number of Drucker laboratory reagents have been developed  that may be useful for successful pursuit of several of the above strategic targets.